Physician profile
Andy Abril
NPI 1447240239
$20,990.56
in general payments reported to CMS, 2019-2025
15 companies · $4,259 in 2025
The $4,259 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $327 · 2021: $389 · 2022: $3,576 · 2023: $6,806 · 2024: $4,941 · 2025: $4,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,490 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,849 · Honoraria: $1,680 · Food and Beverage: $1,642 · Travel and Lodging: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,490.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,849.00 |
| Honoraria | $1,680.00 |
| Food and Beverage | $1,642.24 |
| Travel and Lodging | $1,344.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,219.53 | 2019-2025 | Ofev |
| Abbvie INC. | $2,038.80 | 2024 | |
| Amgen INC. | $2,027.18 | 2019-2025 | Tavneos, Uplizna |
| Ani Pharmaceuticals, INC. | $1,680.00 | 2023 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $1,636.58 | 2023-2025 | Saphnelo |
| Genentech, INC. | $453.10 | 2019-2023 | Actemra |
| Lilly USA, LLC | $237.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $177.04 | 2021-2024 | |
| Horizon Therapeutics Plc | $143.42 | 2020 | |
| Kyowa Kirin, INC. | $125.00 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $111.65 | 2019 | |
| Insmed, INC. | $105.00 | 2019 | |
| Genzyme Corporation | $35.28 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Abril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.